Immunocore Holdings (IMCR) | Stock Overview & Key Data
Immunocore Holdings Performance Comparison
Stock Range
Today's Range
Low: $32.07
High: $33.10
on August 21, 2025
52 Week Range
Low: $23.15
High: $39.33
on April 9, 2025
on June 4, 2025
All-Time High: $76.98 on January 29, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.6B
EPS
-0.41
P/E Ratio (TTM)
-31.71
Forward P/E
-18.89
P/B Ratio
4.19
PEG Ratio
2.43
Div. Yield
N/A
ROE
-5.43%
Beta
0.775
Debt to Equity
112.35
Financial Highlights
Profitability
Gross Margin
98.94%
Operating Margin
-15.18%
Profit Margin
-5.70%
Returns and Earnings
Return on Assets (TTM)
-1.69%
Return on Equity (TTM)
-5.43%
EBITDA
$-24.6M
Net Income (TTM)
$-20.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$7.11
Quarterly Revenue Growth (YoY)
29.90%
Quarterly Earnings Growth (YoY)
29.93%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings IMCR | 1.63B Small-cap | -1.18% | -11.54% | 3.19% | 9.19% | 9.56% | -8.64% | -38.95% | -24.38% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| Cg Oncology CGON | 1.99B Small-cap | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% | -29.82% | -25.83% | -25.83% |
| Adaptive ADPT | 1.99B Small-cap | -2.24% | 22.50% | 38.94% | 52.72% | 104.04% | 159.88% | 20.52% | -69.05% |
| Vericel VCEL | 1.80B Small-cap | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% | -28.10% | 30.92% | 116.49% |
Ownership & Short Interest
Insider Ownership
5.08%
Institutional Ownership
98.51%
Shares Short
8M
Short Ratio
30.80
Short % of Shares Outstanding
22.80%
Average 10-Day Volume
348K
Average 90-Day Volume
292K
Immunocore Holdings Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Immunocore Holdings would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IMCR's 52-week high and low?
- In the last 52 weeks, Immunocore Holdings reached a high of $39.33 (on June 4, 2025) and a low of $23.15 (on April 9, 2025).
- What is the market cap and P/E ratio for IMCR?
- Curious about Immunocore Holdings's size and valuation? Its market capitalization stands at 1.63B. When it comes to valuation, the P/E ratio (trailing twelve months) is -31.71, and the forward P/E (looking ahead) is -18.89.
- Does IMCR pay dividends? If so, what's the yield?
- As for dividends, Immunocore Holdings isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Immunocore Holdings's main competitors or similar companies to consider before investing?
When looking at Immunocore Holdings, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% Cg Oncology
CGON1.99B Healthcare Biotechnology -29.82% -25.83% Adaptive
ADPT1.99B Healthcare Biotechnology 159.88% 20.52% Vericel
VCEL1.80B Healthcare Biotechnology -28.10% 30.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Immunocore Holdings plc – ADR? (e.g., ROE, Debt/Equity)
- To get a sense of Immunocore Holdings's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -5.43%, the Debt to Equity ratio from the most recent quarter is 112.35, and its Gross Profit Margin stands at 98.94%.
- What is the recent revenue and earnings growth for IMCR?
- Looking at Immunocore Holdings's growth, its revenue over the trailing twelve months (TTM) was $356M. Compared to the same quarter last year (YoY), quarterly revenue grew by 29.90%, and quarterly earnings saw a YoY growth of 29.93%.
- How much of IMCR stock is held by insiders and institutions?
- Wondering who owns Immunocore Holdings stock? Company insiders (like executives and directors) hold about 5.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.51%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.